The short answer
Valeriana officinalis may add to diazepam-related drowsiness or impairment. The exact added risk is not measured, so review co-use with the prescriber before adding the product.
What this answer covers
Confirmed Valeriana officinalis root preparations, not an unidentified valerian species.
- Supplement or preparation
- Valeriana officinalis
- Medication ingredient
- diazepam
The alertness effects may overlap
Diazepam can produce sedation and has active metabolites that persist. Supplement guidance describes drowsiness or cautions about other sedating substances, supporting a precaution without an exact-pair rate.
The evidence does not establish a fixed effect
The inspected supplement evidence does not measure diazepam co-use. A trial finding no sleep benefit from valerian does not establish absence of additive impairment.
Consider all medicines and the formulation
Oral, injected and nasal diazepam have different uses and instructions. Other sedatives, organ function and repeated dosing may affect impairment; no safe supplement dose or short gap is established.
Review use and respond to impairment
Tell the prescriber about the exact product and avoid driving while impaired. Do not change diazepam yourself. Slow breathing or unusual difficulty waking requires emergency help.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-drowsiness precaution from exact diazepam labels and identified-species supplement guidance; no exact combination rate or validated spacing.
- Exact scope
- Confirmed Valeriana officinalis root preparations, not an unidentified valerian species. with Diazepam3322 IN; oral, IV/IM and intranasal formulations, active metabolites and study-route limits.
- Medication form and route
- oral medication; intravenous medication; intramuscular medication; intranasal medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed diazepam
CNS-depressant risk; CYP3A4/2C19 formation of active metabolites with prolonged elimination.
How this applies: Exact diazepam RxCUI 3322 IN, with stated salt/formulation/route bridge.
Not midazolam metabolism or proof of exact botanical risk.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed diazepam
Sedation and respiratory precautions with other CNS depressants.
How this applies: Exact diazepam RxCUI 3322 IN, with stated salt/formulation/route bridge.
Bypasses intestinal absorption; oral juice exposure magnitude cannot be transferred.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed diazepam
CNS-depressant and metabolism-related interaction precautions; exact rescue dosing directions.
How this applies: Exact diazepam RxCUI 3322 IN, with stated salt/formulation/route bridge.
Not oral-study dosing or a basis to delay prescribed rescue treatment; rectal preparations not directly studied here.
Source 4: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Possible but unproven sleep-inducing effects; advises against combining valerian with alcohol or sedatives.
How this applies: Original source interpreted for diazepam only within the stated preparation and endpoint limits.
Not a direct diazepam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 5: federal botanical identity and safety guidance
ods.od.nih.gov · Source check Sep 10, 2026
Population: Users of Valeriana officinalis.
The fact sheet covers only V. officinalis among more than 250 valerian species; possible additive sedation is theoretical.
How this applies: Original source interpreted for diazepam only within the stated preparation and endpoint limits.
Not a direct diazepam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Source 6: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 participants with anxiety and insomnia.
Neither botanical improved its primary anxiety/insomnia outcome over placebo.
How this applies: Original source interpreted for diazepam only within the stated preparation and endpoint limits.
Not a direct diazepam combination trial; original preparation, dose and endpoint limits apply. No exact-pair adverse-event rate or protective spacing established.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Prepared exact diazepam article with formulation-specific evidence and uncertainty. |
Article revision: 9a247415881fa092
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.